Fiona Marshall, an experienced biotech executive, has been appointed president of the Novartis Institutes for BioMedical Research, effective 1 November, replacing James Bradner who has held the position since 2016. Dr Marshall is currently global head of discovery, preclinical development and translational medicines at Merck & Co Inc. Prior to this she was a founder and chief scientific officer of Heptares Therapeutics, a UK biotech focused on structure-based drug design. Heptares was acquired by the Sosei Group of Japan in 2015. Dr Marshall holds a BSc in biochemistry from the University of Bath and a PhD in neuroscience from the University of Cambridge, both in the UK.
Novartis announced the appointment on 1 September 2022.
Copyright 2022 Evernow Publishing Ltd